China’s NMPA Unveils Three-Year Smart Supervision Plan for Blood Product Industry
China’s National Medical Products Administration (NMPA) has unveiled the “Three-Year Action Plan for Smart Supervision...
NMPA
China’s NMPA Issues New Supervision Measures for Medical Device Clinical Trials Starting October 2024
The National Medical Products Administration (NMPA) has approved the “Measures for Supervision and Inspection of...
China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...
Beijing Unveils Action Plan to Boost Pharmaceutical and Health Industry by 2026
The Beijing People’s Government has issued an “Action Plan” outlining measures and targets to “Accelerate...
NMPA Releases 80th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 80th batch of reference drugs for...
China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023
The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...
China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation
The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...
ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...
CSPC Pharmaceutical’s βKlotho Monoclonal Antibody JMT202 Receives Clinical Trial Approval from NMPA
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
NMPA Seeks Public Comment on Draft Proposal for Drug Re-Registration Procedures
The National Medical Products Administration (NMPA) of China has released a draft proposal for the...
NMPA Updates In Vitro Diagnostic Reagents Classification List for Enhanced Regulatory Oversigh
The National Medical Products Administration (NMPA) has coordinated the revision and release of the In...
Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation
Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...
China Upgrades Midazolam to Category I Psychotropic Drug List in Regulatory Rescheduling
In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and...
GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises
The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...
China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration
The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...
China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...
China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan
The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...
NMPA Mandates Electronic Permits for Anesthetic Drugs and Psychotropic Substances
The National Medical Products Administration (NMPA) has issued a new notification aimed at enhancing the...
China’s National Adverse Drug Reaction Report for 2023 Highlights Stability in Reporting Trends
The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual...
Shanghai Unveils 17 Measures to Enhance Medical Administration Business Environment
Shanghai’s Medical Product Administration has unveiled a comprehensive set of 17 measures aimed at fostering...